


Calculating Medication Adherence



Patient: Bob N.

	1/1/2017	1/2/2017	1/3/2017	1/4/2017	1/5/2017	1/6/2017	1/7/2017	1/8/2017	1/9/2017	1/10/2017
Metformin	1	1	1	1	1	1	1	0	0	1
Saxagliptin	NA	NA	1	1	1	1	1	1	1	1

Metformin	80%	Saxagliptin	100%
------------------	------------	--------------------	-------------

Figure S1: Process and workflows for calculating medication adherence using a Proportion of Days Covered approach

P-SAM (Parkland Score for Adherence to Medication)

THERAPEUTIC CLASS	PHARMACY CLASS	ADHERENCE RATE	DAYS ADHERENT	FROM DATE	TO DATE	CALCULATED DATE
ACEI/ARB/ARBNI/RI	Example Med: Lisinopril, Losartan	26.30	96	06/03/2018	06/02/2019	06/02/2019
Anticonvulsant - GABA Analogs	Example Med: Gabapentin, Pregabalin	9.86	36	06/03/2018	06/02/2019	06/02/2019
ANTIHYPERGLYCEMICS	INSULINS	100.00	365	06/03/2018	06/02/2019	06/02/2019
Biguanides	Example Med: Metformin	21.36	78	06/03/2018	06/02/2019	06/02/2019
CCB	CALCIUM CHANNEL BLOCKING AGENTS	100.00	1	04/02/2019	04/02/2019	06/02/2019
PSYCHOTHERAPEUTIC DRUGS	ANTI-ANXIETY DRUGS	10.08	36	06/03/2018	05/25/2019	06/02/2019
PSYCHOTHERAPEUTIC DRUGS	SEROTONIN-2 ANTAGONIST/REUPTAKE INHIBITORS (SARIS)	73.33	66	03/05/2019	06/02/2019	06/02/2019
SSRI/SSRI Combo	Example: Citalopram, Fluoxetine	51.82	185	06/03/2018	05/25/2019	06/02/2019
Statin/Statin Combo	Example Med: Atorvastatin	4.93	18	06/03/2018	06/02/2019	06/02/2019

Figure S2: Parkland Score for Adherence to Medications (P-SAM) display in the electronic medical record




Figure S3: Example of biguanide medication adherence dashboard for population health management

Table S1. Diabetes drug classes included in adherence model

SGLT-2 & DPP-4 INHIBITOR COMB.

DPP-4 ENZYME INHIB & THIAZOLIDINEDIONE

DPP-4 INHIBITOR & BIGUANIDE COMB

INCRETIN MIMETICS (GLP-1 RECEPTOR AGONIST)

DPP-4 INHIBITORS & HMG COA REDUCTASE (STATINS)

AMYLIN ANALOG-TYPE

DPP-4 INHIBITORS

SGLT2 INHIBITOR & BIGUANIDE COMB

SODIUM/GLUCOCOTRANSPORTER2 (SGLT2) INHIB

DOPAMINE RECEPTOR AGONISTS

ALPHA-GLUCOSIDASE INHIBITORS

INSULIN-RELEASING STIMULANT & BIGUANIDE COMB

INSULIN-RELEASE STIMULANT TYPE

THIAZOLIDINEDIONE & BIGUANIDE

THIAZOLIDINEDIONE & SULFONYLUREA

THIAZOLIDINEDIONE (PPARG AGONIST)

BIGUANIDE & DIETARY SUPPLEMENT COMB

INSULINS*

* Disclosure that information is based on days' supply of insulin dispensed in the original prescription and does not take into account adjustments in insulin dosing that may have occurred since then (unless they are reflected in a follow-on insulin prescription reflecting the updated dosing).

Table S2. Example correlation of A1c to liraglutide adherence based on fill history (internal data)		
Liraglutide Adherence	Total Population (n = 188)	HbA1c within 90 Days of First Fill (n = 104)
	HbA1c, mg/dL	HbA1c, mg/dL
Adherence Rate <40%	9.15	9.51
Adherence Rate 40-80%	8.52	8.27
Adherence Rate >80%	8.16	7.64